Literature DB >> 32448984

PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.

Mario Sanchez-Canteli1, Rocio Granda-Díaz1,2, Nagore Del Rio-Ibisate1,2, Eva Allonca1,2, Fernando López-Alvarez1,2, Jackeline Agorreta2,3, Irati Garmendia2,3, Luis M Montuenga2,3, Juana M García-Pedrero4,5,6, Juan P Rodrigo7,8,9.   

Abstract

INTRODUCTION: The importance of immune tumor microenvironment in the prognosis of patients with head and neck squamous carcinomas (HNSCC) is increasingly recognized. We analyzed the prognostic relevance of PD-L1 and PD-1 expressions in relation to the infiltration by CD8+ and FOXP3+ tumor-infiltrating lymphocytes (TILs).
METHODS: Samples from 372 surgically treated HPV-negative HNSCC patients were evaluated by immunohistochemistry for PD-L1 expression [both tumor proportion score (TPS) and combined proportion score (CPS)], PD-1 expression in immune cells, and density of infiltrating CD8+ and FOXP3+ TILs. PD-L1 expression and CD8+ TIL density were combined to establish the type of tumor microenvironment.
RESULTS: 29.5% cases exhibited PD-L1 TPS positivity (≥ 1%), whereas PD-L1 CPS positivity (≥ 1%) was observed in 40% cases. 47.5% cases showed positive PD-1 expression (≥ 1%). PD-L1 and PD-1 positivity correlated with a high density of both CD8+ and FOXP3+ TILs. In univariate analysis, PD-L1 TPS positivity (P = 0.026), PD-L1 CPS positivity (P = 0.004), high density of CD8+ TIL (P = 0.001), and high density of FOXP3+ TIL (P = 0.004) were associated with a better disease-specific survival (DSS). However, in multivariate analysis, only high density of CD8+ TIL was associated with a better DSS (P = 0.002). The type of tumor microenvironment correlated with DSS (P = .008), with the better DSS observed in cases with type I (PD-L1 CPS positivity and high density of CD8+ TIL).
CONCLUSIONS: High infiltration by CD8+ TIL is associated with better survival outcomes. Positive PD-L1 expression correlates with a high infiltration by TILs, explaining its association with better prognosis.

Entities:  

Keywords:  Head and neck cancer; PD-L1; Prognosis; Tumor-infiltrating lymphocytes

Year:  2020        PMID: 32448984     DOI: 10.1007/s00262-020-02604-w

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  17 in total

1.  Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma.

Authors:  Atsushi Yamashita; Yoshiyuki Suehara; Takuo Hayashi; Tatsuya Takagi; Daisuke Kubota; Keita Sasa; Nobuhiko Hasegawa; Muneaki Ishijima; Takashi Yao; Tsuyoshi Saito
Journal:  Virchows Arch       Date:  2022-06-15       Impact factor: 4.535

2.  Identification of a novel ceRNA network related to prognosis and immunity in HNSCC based on integrated bioinformatic investigation.

Authors:  Hongbo Liu; Guoli Hei; Lu Zhang; Yanxia Jiang; Haijun Lu
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

3.  Immune Cell Infiltrates and Neutrophil-to-Lymphocyte Ratio in Relation to Response to Chemotherapy and Prognosis in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas.

Authors:  Mario Sánchez-Canteli; Luis Juesas; Esther Redin; Alfonso Calvo; Fernando López; Aurora Astudillo; Luis M Montuenga; Juana M García-Pedrero; Juan P Rodrigo
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

Review 4.  Tumor-Infiltrating Lymphocytes in the Tumor Microenvironment of Laryngeal Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.

Authors:  Juan P Rodrigo; Mario Sánchez-Canteli; Fernando López; Gregory T Wolf; Juan C Hernández-Prera; Michelle D Williams; Stefan M Willems; Alessandro Franchi; Andrés Coca-Pelaz; Alfio Ferlito
Journal:  Biomedicines       Date:  2021-04-28

5.  Histologic evaluation of host immune microenvironment and its prognostic significance in oral tongue squamous cell carcinoma: a comparative study on lymphocytic host response (LHR) and tumor infiltrating lymphocytes (TILs).

Authors:  Bin Xu; Abeer M Salama; Cristina Valero; Avery Yuan; Anjanie Khimraj; Maelle Saliba; Daniella K Zanoni; Ian Ganly; Ronald Ghossein; Snehal G Patel; Nora Katabi
Journal:  Pathol Res Pract       Date:  2021-05-10       Impact factor: 3.309

6.  Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma.

Authors:  Junhui Chen; Jie Yang; Qingchun Xu; Zhenyu Wang; Jun Wu; Liukui Pan; Kai Huang; Chen Wang
Journal:  Biosci Rep       Date:  2021-02-26       Impact factor: 3.840

7.  CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas.

Authors:  Depei Li; Wanming Hu; Xiaoping Lin; Ji Zhang; Zhenqiang He; Sheng Zhong; Xia Wen; Peiyu Zhang; Xiaobing Jiang; Hao Duan; Chengcheng Guo; Jian Wang; Jing Zeng; Zhongping Chen; Yonggao Mou; Ke Sai
Journal:  Front Cell Dev Biol       Date:  2021-03-19

Review 8.  The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy.

Authors:  Saeed Asiry; Gina Kim; Panagiota S Filippou; Luis Rivera Sanchez; David Entenberg; Douglas K Marks; Maja H Oktay; George S Karagiannis
Journal:  Front Immunol       Date:  2021-04-13       Impact factor: 7.561

9.  PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols.

Authors:  Simona Crosta; Renzo Boldorini; Francesca Bono; Virginia Brambilla; Emanuele Dainese; Nicola Fusco; Andrea Gianatti; Vincenzo L'Imperio; Patrizia Morbini; Fabio Pagni
Journal:  Cancers (Basel)       Date:  2021-01-14       Impact factor: 6.639

10.  Immune landscape and subtypes in primary resectable oral squamous cell carcinoma: prognostic significance and predictive of therapeutic response.

Authors:  Pengfei Diao; Yue Jiang; Yuanyuan Li; Xiang Wu; Jin Li; Chen Zhou; Lei Jiang; Wei Zhang; Enshi Yan; Ping Zhang; Xu Ding; Heming Wu; Hua Yuan; Jinhai Ye; Xiaomeng Song; Linzhong Wan; Yunong Wu; Hongbing Jiang; Yanling Wang; Jie Cheng
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.